Inimmune, a biotechnology company based in Missoula, Montana, has accomplished its first outside investment with $22 million in Series A funding. Inimmune participated in the ASCEND Business Advising Cohort in 2019 where executives received technology review and pitch preparation. The investment will fund the advancement of Phase I human clinical trials for late-stage pre-clinical drug candidates in oncology and allergy. Inimmune has been working to develop immunotherapeutics and vaccines since it was founded in 2016. 

Jay Evans, PhD, CEO and President at Inimmune said the partnership with Two Bear Capital for the Series A investment will help grow a “world-class biotech company” in Montana. The company is also partnering with the University of Montana on a COVD-19 vaccine. 

To read the full article click here!
https://inimmune.com/inimmune-raises-22-million-in-series-a-funding-led-by-two-bear-capital/

With a newly awarded research grant, the GPER G-1 Development Group will continue to develop a novel therapeutic for the treatment of diabetes and obesity.  The technology comes out of the University of New Mexico Health Sciences center with research led by Eric Prossnitz, PhD, a professor in and chief of the Division of Molecular Medicine in the Department of Internal Medicine. The National Institutes of Health (NIH) Small Business Technology Transfer (STTR) grant was awarded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Dr. Prossnitz said the funding presents an incredible opportunity to present an innovative approach to treating and preventing diabetes and obesity. GPER G-1 participated in the ASCEND 2020 Business Advising Cohort where executives received technology review and pitch preparation.

UAF scientist turned startup-founder Bahareh Barati took her company, Barati Medical, to the finals of the 2020 Alaska Angel Conference on May 21 and won the People’s Choice Award sponsored by Alaska Airlines. Barati Medical participated in the ASCEND 2020 Business Advising Cohort where executives received technology review and pitch preparation.

Virtici, LLC announced today that it has received a three-year, $3.5 million award from the National Institutes of Health (NIH) to support an Institutional Development Award (IDeA) Center of Biomedical Research Excellence. Virtici has been selected to create and operate a Regional Technology Transfer Accelerator Hub in the Western region (the ASCEND Accelerator Hub: NM, AK, ID, HI, MT, NV and WY).